Patents Assigned to Sequoia Pharmaceuticals
  • RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS
    Publication number: 20100056596
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: March 20, 2009
    Publication date: March 4, 2010
    Applicant: Sequoia Pharmaceuticals
    Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Ravi Rajendran
  • RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS
    Publication number: 20100009935
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: July 16, 2009
    Publication date: January 14, 2010
    Applicant: SEQUOIA PHARMACEUTICALS
    Inventors: John W. Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
  • Resistance-repellent retroviral protease inhibitors
    Patent number: 7507763
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: March 24, 2009
    Assignee: Sequoia Pharmaceuticals
    Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Ravi Rajendran
  • Long Acting Biologically Active Conjugates
    Publication number: 20070207952
    Abstract: The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity in vivo. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein. The complexes are prepared by conjugating a biologically active moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein. The complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule. The invention also provides anti-viral compounds that are inhibitors of viral infection and/or exhibit anti-fusiogenic properties.
    Type: Application
    Filed: March 24, 2004
    Publication date: September 6, 2007
    Applicant: SEQUOIA PHARMACEUTICALS
    Inventors: Abelardo Silva, John Erickson, Michael Eissenstat, Elena Afonina, Sergei Gulnik
  • Resistance-repellent retroviral protease inhibitors
    Publication number: 20060258627
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: July 21, 2006
    Publication date: November 16, 2006
    Applicant: Sequoia Pharmaceuticals
    Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Rajendran
  • Resistance-repellent retroviral protease inhibitors
    Publication number: 20050267074
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: May 9, 2005
    Publication date: December 1, 2005
    Applicant: Sequoia Pharmaceuticals
    Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Rajendran
  • Resistance-repellent retroviral protease inhibitors
    Publication number: 20050209301
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: March 11, 2005
    Publication date: September 22, 2005
    Applicant: SEQUOIA PHARMACEUTICALS
    Inventors: Michael Eissenstat, Tatiana Guerassina